- Home
- ICCT vs QLGN Comparison
ICCT vs QLGN Comparison
Compare ICCT & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCT
- QLGN
- Stock Information
- Founded
- ICCT 1992
- QLGN 1996
- Country
- ICCT United States
- QLGN United States
- Employees
- ICCT N/A
- QLGN N/A
- Industry
- ICCT Computer Software: Prepackaged Software
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ICCT Technology
- QLGN Health Care
- Exchange
- ICCT Nasdaq
- QLGN Nasdaq
- Market Cap
- ICCT 2.9M
- QLGN 2.4M
- IPO Year
- ICCT N/A
- QLGN N/A
- Fundamental
- Price
- ICCT $2.07
- QLGN $3.41
- Analyst Decision
- ICCT
- QLGN
- Analyst Count
- ICCT 0
- QLGN 0
- Target Price
- ICCT N/A
- QLGN N/A
- AVG Volume (30 Days)
- ICCT 31.7M
- QLGN 111.5K
- Earning Date
- ICCT 05-14-2025
- QLGN 04-15-2025
- Dividend Yield
- ICCT N/A
- QLGN N/A
- EPS Growth
- ICCT N/A
- QLGN N/A
- EPS
- ICCT N/A
- QLGN N/A
- Revenue
- ICCT $11,049,477.00
- QLGN N/A
- Revenue This Year
- ICCT N/A
- QLGN N/A
- Revenue Next Year
- ICCT N/A
- QLGN N/A
- P/E Ratio
- ICCT N/A
- QLGN N/A
- Revenue Growth
- ICCT 42.66
- QLGN N/A
- 52 Week Low
- ICCT $0.24
- QLGN $2.96
- 52 Week High
- ICCT $35.80
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- ICCT 55.80
- QLGN 51.52
- Support Level
- ICCT $0.24
- QLGN $3.09
- Resistance Level
- ICCT $5.42
- QLGN $3.78
- Average True Range (ATR)
- ICCT 0.44
- QLGN 0.28
- MACD
- ICCT 0.35
- QLGN 0.05
- Stochastic Oscillator
- ICCT 35.33
- QLGN 39.60
About ICCT iCoreConnect Inc. Common stock
iCoreConnect Inc develops and markets secure cloud-based HIPAA compliant software services focused on compliance, workflow/productivity, and electronic health records systems. Its core services technology can be adopted to other vertical markets that require a high degree of secure data communication, such as the legal, financial, and education fields. It markets secure HIPAA compliant cloud-based software as a service (SaaS) offering under the names of iCoreExchange, iCoreCodeGenius, iCoreSecure, iCoreMD, iCoreDental, iCoreMobile, iCoreHuddle, iCoreRx, iCorePDMP, iCoreEPCS, and iCorePay. The company's software is sold under annual recurring revenue subscriptions. The company has a single reporting segment for reporting purposes focused on the North American market.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.